The company said, “The Directors are confident that the Group and the Company will have sufficient funds to continue to meet their liabilities as they fall due for at least 12 months from the date of approval of the financial statements and therefore have prepared the financial statements on a going concern basis.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OXBDF:
- Oxford Biomedica reports FY24 EPS (GPB 41.75) vs. (GPB 163.11) last year
- Oxford Biomedica vice chair Stuart Henderson to retire
- Oxford Biomedica sees FY25 revenue GBP 160M-GBP 170M
- Oxford BioMedica: Promising Growth and Attractive Valuation Drive Buy Rating
- Oxford BioMedica Reports Robust 2024 Financial Performance and Strategic Expansion